Director Carolyn Bertozzi resigns from Lilly board due to Lycia Therapeutics collaboration

ELI LILLY & Co

Carolyn Bertozzi resigned as independent director effective August 23, 2021, in connection with Lilly's collaboration and licensing agreement with Lycia Therapeutics.
Bertozzi served on the board since 2017, including on Science and Technology and Ethics and Compliance committees.
Resignation did not arise from any disagreement with Lilly's operations, policies, or practices.
Lilly's chairman thanked Bertozzi for her service, citing her scientific expertise.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Carolyn R. Bertozzi

Director

LLY · ELI LILLY & Co

Effective: 2021-08-23
Filed: August 25, 2021, 7:59 PM ET

In connection with the Company’s entry into the collaboration and licensing agreement, Carolyn R. Bertozzi, academic founder of Lycia, resigned from the Company’s Board of Directors, effective August 23, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Carolyn R. Bertozzi resigned as Director at ELI LILLY & Co.

Action: resigned
Role: Director

Exact text from the filing

In connection with the Company’s entry into the collaboration and licensing agreement, Carolyn R. Bertozzi, academic founder of Lycia, resigned from the Company’s Board of Directors, effective August 23, 2021.

View on SEC.gov

ELI LILLY & Co filing history →

Source: SEC EDGAR

accession 0000059478-21-000190

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.